European clearance for Nycomed's Instanyl single-dose nasal spray

5 July 2011

Independent Swiss drugmaker Nycomed, which is the subject of a $13.9 billion takeover by Japan’s Takeda Pharmaceuticals (TYO: 4502), says that the European Commission has granted marketing authorization for its Instanyl (fentanyl) single-dose nasal spray.

The single-dose nasal spray marks another innovation by Nycomed in the management of breakthrough pain in cancer patients and will be available in European countries from September 2011, the company notes. Instanyl was approved in Europe in July 2009 for the treatment of breakthrough pain in cancer patients.

Instanyl fentanyl nasal spray has been developed by Nycomed. It was the first fast acting nasal opioid approved for the management of breakthrough pain in cancer patients, and was first approved in Europe in a multi-dose nasal spray in 2009.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK